In Brief: Clozapine bioequivalence studies
Clozapine bioequivalence studies: FDA will issue a guidance on in vivo bioequivalence studies of the antipsychotic agent clozapine (Sandoz' Clozaril) "within the next few months," agency tells industry in Jan. 31 letter. "If you plan on initiating a clozapine bioequivalence study before this guidance is issued, we encourage you to work with the appropriate institutional review board in selecting the study population to be employed," FDA says. The letter follows reports to FDA of increased side effects seen with clozapine formulations administered to healthy volunteers compared to those seen in the schizophrenic population. At least one generic company, Zenith, has suspended its bio studies of clozapine after side effects in healthy volunteers...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth